Company / Return on Equity (ROE)
Phio Pharmaceuticals Corp. Return on Equity (ROE) History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-155.0%
FY2020
5-year range
-679.3% / -54.2%
FY2016-FY2020
Trend
-185.9%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Phio Pharmaceuticals Corp. reports negative total equity of -155.0% in FY2020. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-155.0% in FY2020 with a 3-year CAGR of -72.1%.
Improved from -679.3% to -155.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -72.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2020, return on equity (roe) decreased 185.9% year-over-year.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2020 | -155.0% | -185.9% |
| FY2019 | -54.2% | +92.0% |
| FY2018 | -679.3% | -719.8% |
| FY2017 | -82.9% | +27.9% |
| FY2016 | -115.0% | - |
| FY2013 | - | - |
| FY2012 | - | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026